文献速递其他结缔组织病

甲泼尼龙治疗极早期系统性硬化症的疗效:「早击早治」随机对照试验结果

Efficacy of methylprednisolone in very early systemic sclerosis: results of the 'Hit Hard and Early' randomized controlled trial.
PubMed 文献 · Rheumatology (Oxford) · 2025-01-01

这项随机对照试验将符合极早期系统性硬化症(SSc)诊断标准、指端肿胀少于3年的成人按2:1随机分配至甲泼尼龙1000 mg静脉注射或安慰剂组,连续3天、每月1次、共3次。主要终点第12周甲床毛细血管密度组间差异为-0.5(95%CI:-1.1,0.2),所有次要结局亦无差异;1年随访中11例(37%)疾病进展,7例(23%)肺功能相关下降,未报告严重不良事件。

要点

  • 极早期SSc患者接受甲泼尼龙1000 mg静脉注射方案后,第12周甲床毛细血管密度与安慰剂组无差异(-0.5,95%CI:-1.1,0.2)。
  • 所有次要结局包括第52周毛细血管密度、巨大毛细血管数量及患者报告结局均无差异。
  • 1年随访中11例(37%)疾病进展,7例(23%)出现相关肺功能下降,未报告严重不良事件。

核心结论

  • 短期甲泼尼龙治疗极早期SSc患者未观察到临床相关疗效,相当比例患者仍出现疾病进展。

研究设计与样本

  • 随机、安慰剂对照试验,2017年2月至2021年2月筛查87例,随机分配30例(女性70%,中位年龄52.9岁,中位病程11.4个月)至甲泼尼龙组(n=21)或安慰剂组(n=9)。

主要发现

  • 第12周甲床毛细血管密度组间差异为-0.5(95%CI:-1.1,0.2),所有次要结局均无差异。
  • 1年随访期间11例(37%)患者疾病进展,7例(23%)患者出现相关肺功能下降,未报告严重不良事件。

关键数值与推荐

  • 纳入标准为指端肿胀少于3年、特异性自身抗体阳性且符合极早期系统性硬化症诊断标准。
  • 干预方案为甲泼尼龙1000 mg静脉注射或安慰剂,连续3天、每月1次、共3次。
  • 主要终点为第12周甲床毛细血管密度。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: We hypothesized that glucocorticoids would induce remission in very early systemic sclerosis (SSc) patients by inhibition of inflammation driving the disease. We examined the efficacy and safety of methylprednisolone in very early SSc. METHODS: In this trial adults with puffy fingers for less than 3 years, specific auto-antibodies and meeting the Very Early Diagnosis of Systemic Sclerosis criteria were randomly assigned (2:1) to methylprednisolone 1000 mg i.v. or placebo for three consecutive days three times with monthly intervals. The primary end point was nailfold capillary density at week 12. Capillary density at 52 weeks, number of megacapillaries and patient-reported outcomes were secondary outcomes. In addition, we assessed disease progression and lung function decline over 52 weeks. We used linear regression analyses adjusted for baseline values and stratification variables to estimate differences between groups. RESULTS: Between February 2017 and February 2021, 87 patients were screened, of whom 30 (70% female, median [interquartile range, IQR] age 52.9 [40.8-60.8] years, median [IQR] disease duration 11.4 [4.6-18.6] months) were randomly assigned to methylprednisolone (n = 21) or placebo (n = 9). We found no difference in nailfold capillary density at 12 weeks (-0.5 [95% CI: -1.1, 0.2]) nor in any of the secondary outcomes. Eleven (37%) patients showed disease progression during 1 year follow-up, and seven (23%) patients had a relevant pulmonary function decline. No serious adverse events were reported. CONCLUSION: No clinically relevant effect of short-term methylprednisolone in patients with very early SSc was observed. A substantial proportion of patients showed disease progression. TRIAL REGISTRATION: clinicaltrials.gov, NCT03059979.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. Kersten BE, Lemmers JMJ, Vanhaecke A, et al. Efficacy of methylprednisolone in very early systemic sclerosis: results of the 'Hit Hard and Early' randomized controlled trial. Rheumatology (Oxford). 2025. PMID: 38552324. doi:10.1093/rheumatology/keae156

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。